Amanda Lewis

June 24, 2022

Amanda Lewis joined Cuneo Gilbert & LaDuca, LLP from the Federal Trade Commission, where she worked as an attorney in the Bureau of Competition since 2012. While at the FTC, she served for over two and a half years as a Counsel-Detailee to the Antitrust Subcommittee of the House Judiciary Committee.

Amanda was one of the primary authors of the Digital Markets Investigation Majority Staff Report and worked on the big tech legislation currently being considered by Congress. Prior to the FTC, Amanda was an associate at Cravath, Swaine & Moore and a law clerk for Judge Lawrence McKenna of the Southern District of New York. She received her B.A. from New York University in 2002 and her J.D. from Columbia Law School in 2008.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor